Antihypertensive treatment and new-onset diabetes mellitus
The various antihypertensive regimens have varying effects on glucose metabolism and the development of diabetes mellitus. Recent large hypertension trials have shown great differences in the development of new-onset diabetes among antihypertensive drug therapies. The incidence of diabetes is unchanged or increased by thiazide diuretics and β-adrenergic blockers, and unchanged or decreased by angiotensin-converting enzyme inhibitors, calcium channel blockers, and angiotensin-receptor blockers. The differences in new-onset diabetes mellitus have not influenced the outcome of cardiovascular mortality and morbidity in all of the large clinical trials, but drug-induced diabetes among hypertensive patients is known to carry the same cardiovascular risk as that seen in patients with previously known diabetes; however, it might take years for the increased risk to become apparent.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 9.ALLHAT Officers and Coordinators: Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. In the ALLHAT study, fewer patients developed new-onset diabetes on antihypertensive treatment with ACEI, CCB, and alpha-blocker compared with the diuretic chlorthalidone. ALLHAT was a huge study in more than 42,000 elderly patients with high cardiovascular risk.CrossRefGoogle Scholar
- 10.Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366–372.CrossRefPubMedGoogle Scholar
- 11.Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031. In the VALUE trial, fewer patients developed new-onset diabetes on antihypertensive treatment with ARB compared with treatment with CCB. VALUE comprised more than 15,000 mostly elderly patients with high cardiovascular risk.CrossRefPubMedGoogle Scholar
- 16.Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985, 727:1–113.Google Scholar
- 17.Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. The CAPPP study, on approximately 11,000 middle-aged hypertensive patients, was the first large, randomized trial that showed that treatment of hypertension with ACEI prevents new-onset diabetes mellitus compared with standard treatment with diruretics/β-blockers.CrossRefPubMedGoogle Scholar
- 19.Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003. The LIFE study was the first trial showing that treatment of hypertension with ARB prevents new-onset diabetes compared with standard treatment for hypertension. LIFE was done in about 9200 hypertensive patients with ECG-LVH ranging in age from 55 to 80 years.CrossRefPubMedGoogle Scholar
- 28.Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741–751.CrossRefPubMedGoogle Scholar
- 38.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805–2816.CrossRefPubMedGoogle Scholar
- 44.NAVIGATOR information site: http:/www.bioportfolio.com/ news/novartis_2.htm. Accessed September 10, 2001.Google Scholar
- 46.Kjeldsen SE, Reims HR, Fagard R, Mancia G: Hypertension. In European Society of Cardiology Textbook of Cardivascular Medicine. Oxford: Blackwell Publishing; 2005:In press.Google Scholar